Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 6, 2012 - Issue 4
Submit an article Journal homepage
231
Views
21
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

What is the current place of azoles in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization

Ritesh Agarwal Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India. [email protected]
Pages 363-371 | Published online: 09 Jan 2014

References

  • Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 135(3), 805–826 (2009).
  • Agarwal R. Allergic bronchopulmonary aspergillosis. In: Textbook of Pulmonary and Critical Care Medicine. Jindal SK, Shankar PS, Raoof S, Gupta D, Aggarwal AN, Agarwal R (Eds). Jaypee Publications, New Delhi, India, 947–970 (2010).
  • Agarwal R, Garg M, Aggarwal AN, Saikia B, Gupta D, Chakrabarti A. Serologic allergic bronchopulmonary aspergillosis (ABPA-S): long-term outcomes. Respir. Med. 106(7), 942–947 (2012).
  • Agarwal R, Singh N, Gupta D. Pulmonary hypertension as a presenting manifestation of allergic bronchopulmonary aspergillosis. Indian J. Chest Dis. Allied Sci. 51(1), 37–40 (2009).
  • Denning DW, O’Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: a summary of the evidence. Eur. Respir. J. 27(3), 615–626 (2006).
  • Denning DW, O’Driscoll BR, Powell G et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study. Am. J. Respir. Crit. Care Med. 179(1), 11–18 (2009).
  • Agarwal R. Severe asthma with fungal sensitization. Curr. Allergy Asthma Rep. 11(5), 403–413 (2011).
  • Agarwal R, Gupta D. Severe asthma and fungi: current evidence. Med. Mycol. 49(Suppl. 1), S150–S157 (2011).
  • Agarwal R, Gupta D, Aggarwal AN, Behera D, Jindal SK. Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India. Chest 130(2), 442–448 (2006).
  • Agarwal R, Gupta D, Aggarwal AN, Saxena AK, Chakrabarti A, Jindal SK. Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients. Chest 132(4), 1183–1190 (2007).
  • Agarwal R, Gupta D, Aggarwal AN et al. Clinical significance of decline in serum IgE levels in allergic bronchopulmonary aspergillosis. Respir. Med. 104(2), 204–210 (2010).
  • Agarwal R, Khan A, Gupta D, Aggarwal AN, Saxena AK, Chakrabarti A. An alternate method of classifying allergic bronchopulmonary aspergillosis based on high-attenuation mucus. PLoS ONE 5(12), e15346 (2010).
  • Patterson R, Greenberger PA, Halwig JM, Liotta JL, Roberts M. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch. Intern. Med. 146(5), 916–918 (1986).
  • Frauman AG. An overview of the adverse reactions to adrenal corticosteroids. Adverse Drug React. Toxicol. Rev. 15(4), 203–206 (1996).
  • Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96(1), 23–43 (2002).
  • De Beule K, De Doncker P, Cauwenbergh G et al. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982–1987). Mycoses 31(9), 476–485 (1988).
  • Denning DW, Van Wye JE, Lewiston NJ, Stevens DA. Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Chest 100(3), 813–819 (1991).
  • Germaud P, Tuchais E. Allergic bronchopulmonary aspergillosis treated with itraconazole. Chest 107(3), 883 (1995).
  • Nepomuceno IB, Esrig S, Moss RB. Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Chest 115(2), 364–370 (1999).
  • Salez F, Brichet A, Desurmont S, Grosbois JM, Wallaert B, Tonnel AB. Effects of itraconazole therapy in allergic bronchopulmonary aspergillosis. Chest 116(6), 1665–1668 (1999).
  • Stevens DA, Schwartz HJ, Lee JY et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N. Engl. J. Med. 342(11), 756–762 (2000).
  • Skov M, Hoiby N, Koch C. Itraconazole treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Allergy 57(8), 723–728 (2002).
  • Wark PA, Hensley MJ, Saltos N et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J. Allergy Clin. Immunol. 111(5), 952–957 (2003).
  • Wark P. Pathogenesis of allergic bronchopulmonary aspergillosis and an evidence-based review of azoles in treatment. Respir. Med. 98(10), 915–923 (2004).
  • Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J. Antimicrob. Chemother. 26(4), 561–566 (1990).
  • Chishimba L, Niven RM, Cooley J, Denning DW. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J. Asthma 49(4), 423–433 (2012).
  • Hogan C, Denning DW. Allergic bronchopulmonary aspergillosis and related allergic syndromes. Semin. Respir. Crit. Care Med. 32(6), 682–692 (2011).
  • Wark PA, Gibson PG. Allergic bronchopulmonary aspergillosis: new concepts of pathogenesis and treatment. Respirology 6(1), 1–7 (2001).
  • McCarthy DS, Pepys J. Allergic broncho-pulmonary aspergillosis. Clinical immunology. 2. Skin, nasal and bronchial tests. Clin. Allergy 1(4), 415–432 (1971).
  • Chakrabarti A, Sethi S, Raman DS, Behera D. Eight-year study of allergic bronchopulmonary aspergillosis in an Indian teaching hospital. Mycoses 45(8), 295–299 (2002).
  • Fairs A, Agbetile J, Hargadon B et al. IgE sensitisation to Aspergillus fumigatus is associated with reduced lung function in asthma. Am. J. Respir. Crit. Care Med. 182(11), 1362–1368 (2010).
  • Denning DW, Park S, Lass-Florl C et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin. Infect. Dis. 52(9), 1123–1129 (2011).
  • Agbetile J, Fairs A, Desai D et al. Isolation of filamentous fungi from sputum in asthma is associated with reduced post-bronchodilator FEV(1). Clin. Exp. Allergy 42(5), 782–791 (2012).
  • Abruzzo GK, Fromtling RA, Turnbull TA, Giltinan DM. Effects of bifonazole, fluconazole, itraconazole, and terbinafine on the chemiluminescence response of immune cells. J. Antimicrob. Chemother. 20(1), 61–68 (1987).
  • Pawelec G, Jaschonek K, Ehninger G. The anti-fungal agent itraconazole exerts immunosuppressive effects on alloreactivity but not on natural immunity in vitro. Int. J. Immunopharmacol. 13(7), 875–879 (1991).
  • Pawelec G, Ehninger G, Rehbein A, Schaudt K, Jaschonek K. Comparison of the immunosuppressive activities of the antimycotic agents itraconazole, fluconazole, ketoconazole and miconazole on human T-cells. Int. J. Immunopharmacol. 13(2–3), 299–304 (1991).
  • Kim JH, Ahn YK. The effects of itraconazole on the immune responses in ICR mice. J. Toxicol. Sci. 19(1), 7–15 (1994).
  • Kanda N, Enomoto U, Watanabe S. Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis. J. Invest. Dermatol. 117(6), 1635–1646 (2001).
  • Ausaneya U, Kawada A, Aragane Y. Itraconazole suppresses an elicitation phase of a contact hypersensitivity reaction. J. Invest. Dermatol. 126(5), 1028–1035 (2006).
  • Simitsopoulou M, Roilides E, Likartsis C et al. Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus. Antimicrob. Agents Chemother. 51(3), 1048–1054 (2007).
  • Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin. Pharmacol. Ther. 64(4), 363–368 (1998).
  • Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur. J. Clin. Pharmacol. 56(1), 57–60 (2000).
  • Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S. Iatrogenic adrenal insufficiency as a side effect of combined treatment of itraconazole and budesonide. Eur. Respir. J. 20(1), 127–133 (2002).
  • Shale DJ, Faux JA, Lane DJ. Trial of ketoconazole in non-invasive pulmonary aspergillosis. Thorax 42(1), 26–31 (1987).
  • Fournier EC. Trial of ketoconazole in allergic bronchopulmonary aspergillosis. Thorax 42(10), 831 (1987).
  • Currie DC, Lueck C, Milburn HJ et al. Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis. Thorax 45(6), 447–450 (1990).
  • Ward GW Jr Woodfolk JA, Hayden ML, Jackson S, Platts-Mills TA. Treatment of late-onset asthma with fluconazole. J. Allergy Clin. Immunol. 104(3 Pt 1), 541–546 (1999).
  • Rai SP, Panda BN, Bhargava S. Treatment of allergic bronchopulmonary aspergillosis with fluconazole and itraconazole. Med. J. Armed Forces India 60(2), 128–130 (2004).
  • Hilliard T, Edwards S, Buchdahl R et al. Voriconazole therapy in children with cystic fibrosis. J. Cyst. Fibros. 4(4), 215–220 (2005).
  • Glackin L, Leen G, Elnazir B, Greally P. Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Ir. Med. J. 102(1), 29 (2009).
  • Pasqualotto AC, Powell G, Niven R, Denning DW. The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis. Respirology 14(8), 1121–1127 (2009).
  • Van Cutsem J, Van Gerven F, Van de Ven MA, Borgers M, Janssen PA. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob. Agents Chemother. 26(4), 527–534 (1984).
  • Wark PA, Gibson PG, Wilson AJ. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst. Rev. 3, CD001108 (2004).
  • Burgel PR, Baixench MT, Amsellem M et al. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob. Agents Chemother. 56(2), 869–874 (2012).
  • Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Monzon A, Cuenca-Estrella M. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52(7), 2468–2472 (2008).
  • Agarwal R, Khan A, Aggarwal AN, Gupta D. Is the SMART approach better than other treatment approaches for prevention of asthma exacerbations? A meta-analysis. Monaldi Arch. Chest Dis. 71(4), 161–169 (2009).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.